Redox-metabolic circuits as a central regulator of T cell-based immunotherapy - Report - MDSpire

Redox-metabolic circuits as a central regulator of T cell-based immunotherapy

  • By

  • Sarah McPhedran

  • Tian Zhao

  • Julian J. Lum

  • May 14, 2026

Share

Clinical Report: Metabolic and Redox Pathways as Key Regulators in T Cell Immunotherapy

Overview

This review highlights the critical role of metabolic and redox pathways in T cell immunotherapy, particularly in solid tumors. It emphasizes the interconnectedness of reactive oxygen species (ROS), methionine metabolism, and GCN2 signaling in regulating T cell function and responses to environmental stress.

Background

T cell-based immunotherapies have revolutionized cancer treatment, yet their effectiveness is often limited by the challenging tumor microenvironment. Understanding the metabolic and redox pathways that influence T cell activation and function is essential for enhancing therapeutic outcomes, particularly in solid tumors where nutrient availability and oxidative stress are significant factors.

Data Highlights

No numerical data provided in the article.

Key Findings

  • Physiological ROS are crucial for T cell receptor signaling and cytotoxicity.
  • Excessive oxidative stress can lead to T cell exhaustion and apoptosis.
  • GCN2 links amino acid availability to T cell metabolic and transcriptional programs.
  • Manipulating methionine availability can yield context-dependent outcomes in immunotherapy.
  • Integrated omics and CRISPR-based screening are emerging strategies to modulate T cell metabolism.

Clinical Implications

Therapeutic strategies that target metabolic pathways and redox states may enhance the efficacy of T cell-based immunotherapies. Context-aware interventions, particularly regarding amino acid availability and oxidative stress management, are essential for optimizing treatment outcomes in solid tumors.

Conclusion

The integration of metabolic and redox pathways presents a promising avenue for improving T cell immunotherapy in solid tumors. Further research is needed to refine these approaches for clinical application.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives
  2. Blood Cancer Journal, 2014 -- Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity
  3. Bone Marrow Transplantation, 2025 -- Treg Cell Therapy as a Treatment for Graft-versus-Host Disease
  4. The ASCO Post, 2018 -- Activity of T Cells in Metastatic Melanoma Resistant to Immune Checkpoint Inhibitor Treatment
  5. Melanoma Treatment (PDQ®) - NCI -- NCI PDQ on melanoma treatment
  6. Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting - PMC
  7. Oxidative stress in CAR-T cell therapy: Mechanistic insights and redox-targeted interventions - ScienceDirect
  8. Melanoma Treatment (PDQ®) - NCI
  9. Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting - PMC
  10. Oxidative stress in CAR-T cell therapy: Mechanistic insights and redox-targeted interventions - ScienceDirect

Original Source(s)

Related Content